{"id":"W2892271101","doi":"10.1200/jco.2017.35.15_suppl.5534","title":"Long-term benefit of niraparib treatment of recurrent ovarian cancer (OC).","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"ca_institutions":"University Health Network; BC Cancer Agency","funders":"","keywords":"Medicine; Bevacizumab; Internal medicine; Chemotherapy; Ovarian cancer; Randomization; Randomized controlled trial; Oncology; Progression-free survival; BRCA mutation; Surgery; Cancer; Gastroenterology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006929404,0.0003327968,0.001026032,0.0001673769,0.0001960258,0.0003953903,0.00030158,0.0005306883,0.002286506],"category_scores_gemma":[0.0007763766,0.0001720731,0.0009186342,0.00017527,0.0003005169,0.0003879431,0.0002594468,0.001199943,0.0003586308],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003902951,"about_ca_system_score_gemma":0.0006393712,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005217325,"about_ca_topic_score_gemma":0.001642946,"domain_scores_codex":[0.9997887,0.00008730654,0.00001932895,0.00003704361,0.00002257895,0.00004518061],"domain_scores_gemma":[0.9995188,0.0001068106,0.0001260253,0.00004309753,0.00002294724,0.0001823081],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.6539983,0.01503854,0.01102784,0.001523274,0.001681246,0.0002328968,0.00008338695,0.001940082,0.02017444,0.0001851432,0.003493279,0.2906216],"study_design_scores_gemma":[0.1920408,0.6959736,0.09221051,0.0002383227,0.002375382,0.001027652,0.00005550764,0.002081953,0.006014682,0.0003686502,0.007557193,0.00005572362],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9845049,0.01207162,0.0001932614,0.0002478613,0.0001353525,0.000332989,0.0006994676,0.00005079476,0.001763758],"genre_scores_gemma":[0.993721,0.002767142,0.0003305589,0.0003445839,0.000133772,0.0002274324,0.001064115,0.00000688984,0.001404629],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002286506,"threshold_uncertainty_score":0.007649064,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2896326746587832,"score_gpt":0.5637847703547282,"score_spread":0.274152095695945,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}